{
  "id": "63f03ae6f36125a42600001d",
  "type": "factoid",
  "question": "What is the target of BI 1015550?",
  "ideal_answer": "BI 1015550 is a preferential phosphodiesterase 4B inhibitor that is used for patients with idiopathic pulmonary fibrosis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35569036",
    "http://www.ncbi.nlm.nih.gov/pubmed/35517783",
    "http://www.ncbi.nlm.nih.gov/pubmed/36299369"
  ],
  "snippets": [
    {
      "text": "METHODS: In this phase 2, double-blind, placebo-controlled trial, we investigated the efficacy and safety of BI 1015550, an oral preferential inhibitor of the PDE4B subtype, in patients with idiopathic pulmonary fibrosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35569036",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36299369",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Introduction: BI 1015550 is a phosphodiesterase 4 (PDE4) inhibitor that has antifibrotic properties. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36299369",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BI 1015550 is a novel PDE4 inhibitor showing a preferential enzymatic inhibition of PDE4B.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In summary, the unique preferential inhibition of PDE4B by BI 1015550 and its anticipated improved tolerability in humans, plus its anti-inflammatory and antifibrotic potential, suggest BI 1015550 to be a promising oral clinical candidate for the treatment of IPF and other fibro-proliferative diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35517783",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "phosphodiesterase 4B"
}